KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
INTRODUCTION
The connection between driver mutations and the efficacy of immune checkpoint inhibitors is the focus of intense investigations. In lung adenocarcinoma (LUAD), KEAP1/STK11 alterations have been tied to immunoresistance. Nevertheless, the heterogeneity characterizing immunotherapy efficacy suggests the contribution of still unappreciated events.


METHODS
Somatic interaction analysis of top-ranking mutant genes in LUAD was carried out in the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) (N = 6208). Mutational processes, intratumor heterogeneity, evolutionary trajectories, immunologic features, and cancer-associated signatures were investigated, exploiting multiple data sets (AACR GENIE, The Cancer Genome Atlas [TCGA], TRAcking Cancer Evolution through therapy [Rx]). The impact of the proposed subtyping on survival outcomes was assessed in two independent cohorts of immune checkpoint inhibitor-treated patients: the tissue-based sequencing cohort (Rome/Memorial Sloan Kettering Cancer Center/Dana-Farber Cancer Institute, tissue-based next-generation sequencing [NGS] cohort, N = 343) and the blood-based sequencing cohort (OAK/POPLAR trials, blood-based NGS cohort, N = 304).


RESULTS
Observing the neutral interaction between KEAP1 and TP53, KEAP1/TP53-based subtypes were dissected at the molecular and clinical levels. KEAP1 single-mutant (KEAP1 SM) and KEAP1/TP53 double-mutant (KEAP1/TP53 DM) LUAD share a transcriptomic profile characterized by the overexpression of AKR genes, which are under the control of a productive superenhancer with NEF2L2-binding signals. Nevertheless, KEAP1 SM and KEAP1/TP53 DM tumors differ by mutational repertoire, degree of intratumor heterogeneity, evolutionary trajectories, pathway-level signatures, and immune microenvironment composition. In both cohorts (blood-based NGS and tissue-based NGS), KEAP1 SM tumors had the shortest survival; the KEAP1/TP53 DM subgroup had an intermediate prognosis matching that of pure TP53 LUAD, whereas the longest survival was noticed in the double wild-type group.


CONCLUSIONS
Our data provide a framework for genomically-informed immunotherapy, highlighting the importance of multimodal data integration to achieve a clinically exploitable taxonomy.
['Scalera|Stefano|S|', 'Mazzotta|Marco|M|', 'Corleone|Giacomo|G|', 'Sperati|Francesca|F|', 'Terrenato|Irene|I|', 'Krasniqi|Eriseld|E|', 'Pizzuti|Laura|L|', 'Barba|Maddalena|M|', 'Vici|Patrizia|P|', 'Gallo|Enzo|E|', 'Buglioni|Simonetta|S|', 'Visca|Paolo|P|', 'Pescarmona|Edoardo|E|', 'Marinelli|Daniele|D|', 'De Nicola|Francesca|F|', 'Ciuffreda|Ludovica|L|', 'Goeman|Frauke|F|', 'Fanciulli|Maurizio|M|', 'Giusti|Raffaele|R|', 'Vecchione|Andrea|A|', 'De Maria|Ruggero|R|', 'Cappuzzo|Federico|F|', 'Marchetti|Paolo|P|', 'Ciliberto|Gennaro|G|', 'Maugeri-Saccà|Marcello|M|']
KEAP1 TP53 Lung adenocarcinoma Immunotherapy